Beyond Air (XAIR) unit Beyond Cancer said its Phase 1 clinical trial evaluating a single intratumoral injection of ultra-high-concentration nitric oxide administered as monotherapy for cutaneous or subcutaneous primary or metastatic lesions showed a favorable safety and tolerability profile.
Seven of the 10 patients in the study remained alive between 19 and 37 months after a single dose as of Oct. 1, 2025, the company said Tuesday in a statement.
Most treatment-related adverse events were grade 1, with one serious adverse event of hypoxia that fully resolved, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments